Action

TRKs

Alt Name

Approval Jurisdiction

2018 FDA

Approved for clinical use

Solid tumours with NTRK fusions

Brutto

CAS

1223403-58-4

Commercial Vendor

LOXO-Bayer

Compound Image

Larotrectinib.png

Compound name

Larotrectinib

InChI

InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1

InChI Key

NYNZQNWKBKUAII-KBXCAEBGSA-N

MW

428.40

PubChem CID

46188928

Reference

Reference 2

SMILES

C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F

Approved Drug List

1